Positive Phase 2 Clinical Trial Results with Qnexa

May 12, 2006

In phase 2 clinical trial, Qnexa has produced positive response for solving the obesity problem. Qnexa is a proprietary pharmaceutical treatment containing low doses of the active ingredients phentermine and topiramate.

Drug's developer VIVUS, Inc. (NASDAQ: VVUS) announced positive results from a 200-patient, double-blind, placebo-controlled clinical trial of Qnexa(TM). In the study conducted by Duke University Medical Center, more than half of 50 obese patients in the Qnexa treatment group experienced 10% or more total body weight loss during the 24-week study period.

"The weight loss observed in this trial is quite impressive," said Dr. Kishore M. Gadde, Director, Obesity Clinical Trials Program, Duke University Medical Center.

Although, two active ingredients phentermine and topiramate of Qnexa are being approved by Food and Drugs Administration (FDA), this time it is very hard to make Qnexa available in market .

"We believe that by combining the activity of each of these compounds, Qnexa simultaneously addresses the two main mechanisms that impact eating behavior," said Day. "Qnexa could be the first product to significantly affect both excessive hunger and the inability to feel satisfied

 

Read the complete news article here:
http://www.acompliareport.com/News/news-051206.htm